Joining the discussion are Oliver Crook, Bloomberg News Europe Correspondent, who shares insights on the latest U.S.-China tariff negotiations, and Brooke Sutherland, Boston Bureau Chief with a keen eye on industry trends. Kabir Nath, CEO of Compass Pathways, discusses the groundbreaking potential of synthetic psilocybin for treating depression. They dive into U.S.-China trade dynamics, the strategic interests at play, and the promising future of psychedelic therapy, highlighting both economic and mental health impacts.
